<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02783170</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00071192</org_study_id>
    <nct_id>NCT02783170</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women</brief_title>
  <acronym>Tdap/IIV</acronym>
  <official_title>A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot, prospective, randomized, open-label clinical trial. During the study,
      pregnant women will be randomized (1:1) to receive co-administration of a single
      intramuscular (IM) 0.5 mL dose of US-licensed inactivated influenza vaccine (IIV) and a
      single intramuscular (IM) 0.5 mL dose of US-licensed Tetanus toxoid, reduced diphtheria
      toxoid and acellular pertussis vaccine adsorbed (Tdap) or sequential administration of the
      vaccines (IIV followed by Tdap ~ 21 days later). Vaccines will be administered by licensed
      study personnel.

      Prior Tdap/Td/TT and influenza vaccine history will be verified by medical record review when
      possible.

      Injection-site (local) and systemic reaction data will be assessed on vaccination day and
      during the 7 days following vaccination using either identical web-based or paper diaries,
      depending on study participant preference.

      Maternal serum samples will be collected for antibody titers relevant to the Tdap and
      Influenza at time points that include: prior to vaccination(s), ~21 days post vaccination(s),
      and at delivery. Additionally, cord blood serum will be analyzed for the same antibody
      titers.

      Pregnant women will be followed with comprehensive obstetric and neonatal outcomes obtained
      from medical record review.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">May 10, 2018</completion_date>
  <primary_completion_date type="Actual">April 3, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration</measure>
    <time_frame>8 days post vaccine administration</time_frame>
    <description>Percentage of injection-site reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 1</measure>
    <time_frame>8 days post vaccine administration</time_frame>
    <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 4</measure>
    <time_frame>8 days post vaccine administration</time_frame>
    <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pertussis Serum Antibody Levels, as Measured by Geometric Mean Titers</measure>
    <time_frame>Pre-vaccination and approximately 21 days post vaccination and at Delivery</time_frame>
    <description>Measurement of serum antibody levels to pertussis antigens, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroprotection as Determined by Diphtheria Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</measure>
    <time_frame>Pre vaccination and approximately 21 days post vaccination and at Delivery</time_frame>
    <description>Measurement of serum antibody levels to diphtheria toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroprotection as Determined by Tetanus Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</measure>
    <time_frame>21 days post vaccination</time_frame>
    <description>Measurement of serum antibody levels to tetanus toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroprotection as Determined by Influenza Serum Antibody Levels (≥1:40) (Pre- and Post-immunization) and Seroconversion (4-fold Rise From Baseline or a Change From &lt;1:10 to ≥1:40) )</measure>
    <time_frame>Pre and 21 days post vaccination and at Delivery</time_frame>
    <description>Measurement of serum antibody levels to influenza antigens in maternal blood and infant cord blood obtained at delivery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Recruited Enrollment Period</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of subjects recruited during 4 month enrollment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility as Measured by Participant Retention (Percentage of Participants Who Complete All Visits)</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of participants that completed all in-person and delivery visits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Reported as Percentage of Reactogenicity Data Collected</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of reactogenicity data days reported (days reported / total possible days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Reported as Percentage of Adequate Biospecimens Collected</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of samples collected (sample timepoints collected / total possible sample timepoints)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Reported as Percentage of Timely Collected Biospecimens</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Timeliness is defined as collected within the visit window</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Maternal Outcomes</measure>
    <time_frame>Up to the 6-week postpartum visit</time_frame>
    <description>The number of participants with adverse maternal outcomes at delivery. Missing data is data not collected or unavailable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Infant Outcomes Based on Medical Record Review</measure>
    <time_frame>approximately 2 months</time_frame>
    <description>Number of participants with adverse infant outcomes. Missing data is data not collected or unavailable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Chorioamnionitis</measure>
    <time_frame>at the time of delivery</time_frame>
    <description>Percentage of participants with clinical chorioamnionitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Histologic Chorioamnionitis on Surgical Pathology Examination of Placental Tissue</measure>
    <time_frame>after delivery, approximately up to 2 weeks</time_frame>
    <description>Percentage of participants with histologic chorioamnionitis on surgical pathology examination of placental tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Measured by Percentage of Blood Samples in Testable Condition</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of blood samples received in testable condition (sufficient volume and quality)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Measured by Percentage of Blood Samples in With Sufficient Volume for Testing</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of blood samples received with sufficient volume for testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility as Measured by Percentage of Testable Blood Samples Completed</measure>
    <time_frame>Approximately 1 year</time_frame>
    <description>Percentage of testable (sufficient volume and quality) blood samples completed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Simultaneous vaccination arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential vaccination arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus, Diphtheria, and Pertussis Vaccine</intervention_name>
    <arm_group_label>Sequential vaccination arm</arm_group_label>
    <arm_group_label>Simultaneous vaccination arm</arm_group_label>
    <other_name>Tdap</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2016-2017 Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <arm_group_label>Sequential vaccination arm</arm_group_label>
    <arm_group_label>Simultaneous vaccination arm</arm_group_label>
    <other_name>Flu vaccine</other_name>
    <other_name>2016-2017 Flu vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2017-2018 Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <arm_group_label>Sequential vaccination arm</arm_group_label>
    <arm_group_label>Simultaneous vaccination arm</arm_group_label>
    <other_name>Flu vaccine</other_name>
    <other_name>2017-2018 Flu vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant, as determined by medical history; 18 - 45 years of age inclusive

          2. Intention of receiving Tdap and IIV vaccines based on Advisory Committee on
             Immunization Practices (ACIP) recommendations

          3. Willing to provide written informed consent prior to initiation of any study
             procedures

          4. Singleton gestation ≥ 26 weeks 0 days gestation - ≤32 weeks 0 days gestation at the
             time of Visit 1 vaccination based on reconciliation of last menstrual period and
             ultrasound dating. Estimated due date (EDD) and Gestational Age (GA) - EDD will be
             based on reconciliation of a &quot;sure&quot; first day of the last menstrual period (LMP) and
             earliest dating ultrasound. If the LMP is uncertain, then the earliest dating
             ultrasound will be used to determine EDD and GA. If the ultrasound derived-EDD is in
             agreement with sure-LMP derived EDD, then the LMP-derived EDD is used to determine GA.
             If the ultrasound derived EDD is not in agreement with the LMP-derived EDD, the
             ultrasound-derived EDD is used to determine GA.

          5. English or Spanish literate

          6. Intention of being available for entire study period and complete all relevant study
             procedures, including follow-up phone calls and collection of delivery information.

        Exclusion Criteria:

          1. For subjects enrolling during the 2016-2017 influenza season: IIV/LAIV receipt during
             2016-2017 influenza season prior to study enrollment

          2. For subjects enrolling during the 2017-2018 influenza season: IIV/LAIV receipt during
             2017-2018 influenza season prior to study enrollment

             2. Tdap/Td/TT receipt during current pregnancy prior to study enrollment 3. Has
             immunosuppression as a result of an underlying illness or treatment, or use of
             anti-cancer chemotherapy or radiation therapy within the preceding 36 months.

             4. Has an active neoplastic disease (excluding non-melanoma skin cancer), a history of
             any hematologic malignancy, current bleeding disorder, or taking anticoagulants (daily
             low dose aspirin may be acceptable).

             5. Has a history of receiving immunoglobulin or other blood product (with exception of
             Rhogam) within the 3 months prior to enrollment in this study.

             6. Known to have pre-existing diabetes mellitus or an autoimmune disorder. 7. Febrile
             illness within the last 24 hours or an oral temperature &gt;/= 100.4°F (&gt;/= 38.0°C) prior
             to IIV or Tdap administration 8. Contraindication to IIV receipt including history of
             severe allergic reaction after a previous dose of any influenza vaccine; or to a
             vaccine component, including egg protein 9. Contraindication to Tdap receipt including
             history of severe allergic reaction after a previous dose of any tetanus toxoid-,
             diphtheria toxoid-, or pertussis antigen-containing vaccine or encephalopathy within 7
             days of administration of a previous dose of a pertussis antigen-containing vaccine
             that is not attributable to another identifiable cause 10. Arthus-type
             hypersensitivity reaction following a prior dose of a tetanus toxoid-containing
             vaccine within the last 10 years 11. Any condition that may interfere with assessment
             of local injection site reactions, e.g. lymphadenectomy or obscuring tattoos 12.
             History of Guillain-Barré syndrome within 6 weeks of a prior dose of any tetanus
             toxoid-, diphtheria toxoid- or pertussis antigen-containing vaccine or influenza
             vaccine 13. Known or suspected impairment of immunologic function including infection
             with HIV, hepatitis B or C 14. Use of immunosuppressive or cytotoxic drugs except
             receipt of oral or parenteral (intravenous, subcutaneous or intramuscular)
             corticosteroids 30 or more days prior to enrollment. Persons who have used oral or
             parenteral corticosteroids within 12 months prior to enrollment may be enrolled if the
             longest course of therapy was less than 14 consecutive days and no dose was given
             within 30 days of enrollment. Intraarticular, bursal, tendon, or epidural injections
             of corticosteroids are permissible if the most recent injection was 30 or more days
             prior to enrolment. Persons applying topically corticosteroid in either upper arm
             (i.e. injection site) may be enrolled 1 or more days after their therapy is completed.
             Corticosteroids administered topically at non-injection sites, by inhalation or
             intranasally are permissible 15. Receipt of any licensed vaccine within 14 days prior
             to study vaccination or planning receipt of any vaccines (except study vaccines) prior
             to Visit 7 follow up.

             16. Receipt of live vaccine during current pregnancy. 17. High risk for preterm birth
             (active preterm labor, short cervix, cervical cerclage, receipt of antenatal
             corticosteroids for fetal lung maturity prior to Visit 1) 18. Antenatal ultrasound
             diagnosis of fetal growth restriction, defined as &lt; 10th percentile estimated fetal
             weight for gestational age 19. Known fetal congenital anomaly, e.g. genetic
             abnormality or malformation based on antenatal ultrasound 20. Any condition which, in
             the opinion of the investigators, may pose a health risk to the subject or interfere
             with the evaluation of the study objectives.

             21. Anyone who is a relative of any research study personnel 22. Anyone who is an
             employee of any research study personnel 23. Anyone who is already enrolled or plans
             to enroll in another clinical trial with an investigational product. Co-enrollment in
             observational or behavioral intervention studies are allowed at any time.

             24. Previous participation in the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geeta Swamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centers for Disease Control and Prevention</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2016</study_first_posted>
  <results_first_submitted>March 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2019</results_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tdap vaccine</keyword>
  <keyword>Flu vaccine</keyword>
  <keyword>vaccines in pregnancy</keyword>
  <keyword>immunizations in pregnancy</keyword>
  <keyword>Whooping Cough</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Influenza</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT02783170/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Simultaneous Vaccination Arm</title>
          <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
        <group group_id="P2">
          <title>Sequential Vaccination Arm</title>
          <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="42">Added subject randomized to sequential but got simultaneous.</participants>
                <participants group_id="P2" count="38">Excluded sub. randomized but not vaccinated. Excluded sub. randomized to seq. but got simultaneous.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>Simultaneous Vaccination Arm</title>
          <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
        <group group_id="B2">
          <title>Sequential Vaccination Arm</title>
          <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 21 days later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Maternal Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="17" upper_limit="42"/>
                    <measurement group_id="B2" value="25.5" lower_limit="18" upper_limit="39"/>
                    <measurement group_id="B3" value="26" lower_limit="17" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recent Tdap Vaccine within 2 years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Recent Flu Vaccine within 2 years</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age in Weeks at Visit 1</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" lower_limit="25.7" upper_limit="31.7"/>
                    <measurement group_id="B2" value="28" lower_limit="24.3" upper_limit="31.4"/>
                    <measurement group_id="B3" value="28.7" lower_limit="24.3" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational Age in Weeks at Visit 4</title>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.6" lower_limit="29.0" upper_limit="36.4"/>
                    <measurement group_id="B2" value="31.9" lower_limit="27.4" upper_limit="35.4"/>
                    <measurement group_id="B3" value="32.3" lower_limit="27.4" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration</title>
        <description>Percentage of injection-site reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
        <time_frame>8 days post vaccine administration</time_frame>
        <population>Safety Population - subjects that were randomized and received the study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection-site Reactions Post Tdap and IIV4 Administration</title>
          <description>Percentage of injection-site reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
          <population>Safety Population - subjects that were randomized and received the study intervention</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flu Pain : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.5" lower_limit="31.5" upper_limit="63.9"/>
                    <measurement group_id="O2" value="48.6" lower_limit="31.9" upper_limit="65.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Pain : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="22.7" upper_limit="54.2"/>
                    <measurement group_id="O2" value="45.9" lower_limit="29.5" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Pain : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Pain : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Tenderness : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" lower_limit="18.6" upper_limit="49.1"/>
                    <measurement group_id="O2" value="54.1" lower_limit="36.9" upper_limit="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Tenderness : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="38.5" upper_limit="70.7"/>
                    <measurement group_id="O2" value="37.8" lower_limit="22.5" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Tenderness : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="4.2" upper_limit="26.8"/>
                    <measurement group_id="O2" value="8.1" lower_limit="1.7" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Tenderness : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Pain : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="38.5" upper_limit="70.7"/>
                    <measurement group_id="O2" value="70.6" lower_limit="52.5" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Pain : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="16.6" upper_limit="46.5"/>
                    <measurement group_id="O2" value="14.7" lower_limit="5.0" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Pain : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="2.8" upper_limit="23.7"/>
                    <measurement group_id="O2" value="14.7" lower_limit="5.0" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Pain : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Tenderness : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="22.7" upper_limit="54.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="32.4" upper_limit="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Tenderness : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="22.7" upper_limit="54.2"/>
                    <measurement group_id="O2" value="17.6" lower_limit="6.8" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Tenderness : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="10.8" upper_limit="38.5"/>
                    <measurement group_id="O2" value="29.4" lower_limit="15.1" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Tenderness : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Redness : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="79.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="83.8" lower_limit="68.0" upper_limit="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Redness : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="1.6" upper_limit="20.4"/>
                    <measurement group_id="O2" value="13.5" lower_limit="4.5" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Redness : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.7" lower_limit="0.7" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Redness : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Swelling : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="79.6" upper_limit="98.4"/>
                    <measurement group_id="O2" value="89.2" lower_limit="74.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Swelling : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="1.6" upper_limit="20.4"/>
                    <measurement group_id="O2" value="8.1" lower_limit="1.7" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Swelling : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.7" lower_limit="0.7" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flu Swelling : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Redness : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="70.2" upper_limit="94.3"/>
                    <measurement group_id="O2" value="82.4" lower_limit="65.5" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Redness : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Redness : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Redness : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Swelling : None</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="67.2" upper_limit="92.7"/>
                    <measurement group_id="O2" value="85.3" lower_limit="68.9" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Swelling : Mild</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="7.3" upper_limit="32.8"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Swelling : Moderate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tdap Swelling : Severe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 1</title>
        <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
        <time_frame>8 days post vaccine administration</time_frame>
        <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 1</title>
          <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
          <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="91.2" upper_limit="100"/>
                    <measurement group_id="O2" value="94.6" lower_limit="81.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="76.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="1.6" upper_limit="20.4"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="48.3" upper_limit="79.4"/>
                    <measurement group_id="O2" value="78.4" lower_limit="61.8" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="9.1" upper_limit="35.6"/>
                    <measurement group_id="O2" value="18.9" lower_limit="8.0" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="76.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="76.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="91.9" lower_limit="78.1" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="8.1" lower_limit="1.7" upper_limit="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="73.2" upper_limit="95.8"/>
                    <measurement group_id="O2" value="89.2" lower_limit="74.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="2.8" upper_limit="23.7"/>
                    <measurement group_id="O2" value="10.8" lower_limit="3.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="48.3" upper_limit="79.4"/>
                    <measurement group_id="O2" value="78.4" lower_limit="61.8" upper_limit="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="9.1" upper_limit="35.6"/>
                    <measurement group_id="O2" value="16.2" lower_limit="6.2" upper_limit="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="53.5" upper_limit="83.4"/>
                    <measurement group_id="O2" value="75.7" lower_limit="58.8" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="18.9" lower_limit="8.0" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="67.2" upper_limit="92.7"/>
                    <measurement group_id="O2" value="91.9" lower_limit="78.1" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="5.7" upper_limit="29.8"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="5.4" lower_limit="0.7" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="73.2" upper_limit="95.8"/>
                    <measurement group_id="O2" value="89.2" lower_limit="74.6" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="1.6" upper_limit="20.4"/>
                    <measurement group_id="O2" value="10.8" lower_limit="3.0" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="70.2" upper_limit="94.3"/>
                    <measurement group_id="O2" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="0.6" upper_limit="16.9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="0.1" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="2.8" upper_limit="23.7"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="8.8">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="9.5">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 4</title>
        <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
        <time_frame>8 days post vaccine administration</time_frame>
        <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Systemic Reactions Post Tdap and IIV4 Administration - Visit 4</title>
          <description>Percentage of systemic reactions will be compared in simultaneous and sequential groups as determined by self-assessment via memory aid</description>
          <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O2" value="82.4" lower_limit="65.5" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Aches : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.7" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Rash : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills Shivering : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="97.1" lower_limit="84.7" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2" lower_limit="68.7" upper_limit="94.0"/>
                    <measurement group_id="O2" value="85.3" lower_limit="68.9" upper_limit="95.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" lower_limit="2.9" upper_limit="24.8"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O2" value="79.4" lower_limit="62.1" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="14.7" lower_limit="5.0" upper_limit="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="94.1" lower_limit="80.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Pain : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="10.3">Cannot estimate lower bound as percentage is 0</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="82.4" lower_limit="65.5" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="8.8" lower_limit="1.9" upper_limit="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0.1" upper_limit="13.8"/>
                    <measurement group_id="O2" value="5.9" lower_limit="0.7" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="91.2" lower_limit="76.3" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="0.6" upper_limit="17.7"/>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting : Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="9.3">Cannot estimate lower bound as percentage is 0</measurement>
                    <measurement group_id="O2" value="2.9" lower_limit="0.1" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pertussis Serum Antibody Levels, as Measured by Geometric Mean Titers</title>
        <description>Measurement of serum antibody levels to pertussis antigens, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
        <time_frame>Pre-vaccination and approximately 21 days post vaccination and at Delivery</time_frame>
        <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Pertussis Serum Antibody Levels, as Measured by Geometric Mean Titers</title>
          <description>Measurement of serum antibody levels to pertussis antigens, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
          <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
          <units>Concentration (IU/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination - FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="18.5" upper_limit="41.0"/>
                    <measurement group_id="O2" value="37.0" lower_limit="23.8" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Vaccination - FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" lower_limit="46.9" upper_limit="162.4"/>
                    <measurement group_id="O2" value="20.8" lower_limit="10.5" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Vaccination - PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8" lower_limit="27.3" upper_limit="73.7"/>
                    <measurement group_id="O2" value="47.1" lower_limit="26.4" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Vaccination - PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="5.1" upper_limit="11.9"/>
                    <measurement group_id="O2" value="5.9" lower_limit="3.5" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination - FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.3" lower_limit="135.0" upper_limit="217.7"/>
                    <measurement group_id="O2" value="262.1" lower_limit="201.5" upper_limit="341.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination - FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="55.9" upper_limit="178.7"/>
                    <measurement group_id="O2" value="19.7" lower_limit="10.2" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination - PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.1" lower_limit="178.1" upper_limit="329.2"/>
                    <measurement group_id="O2" value="360.4" lower_limit="240.8" upper_limit="539.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination - PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6" lower_limit="26.8" upper_limit="52.9"/>
                    <measurement group_id="O2" value="38.6" lower_limit="28.4" upper_limit="52.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal - FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" lower_limit="89.9" upper_limit="155.6"/>
                    <measurement group_id="O2" value="199.8" lower_limit="146.7" upper_limit="272.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal - FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" lower_limit="44.0" upper_limit="149.9"/>
                    <measurement group_id="O2" value="18.9" lower_limit="10.3" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal - PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.1" lower_limit="122" upper_limit="248.5"/>
                    <measurement group_id="O2" value="297.1" lower_limit="194.7" upper_limit="453.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal - PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8" lower_limit="19.3" upper_limit="37.4"/>
                    <measurement group_id="O2" value="27.9" lower_limit="19.4" upper_limit="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood - FHA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182" lower_limit="137" upper_limit="241.8"/>
                    <measurement group_id="O2" value="265.6" lower_limit="195.8" upper_limit="360.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood - FIM</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.2" lower_limit="67.5" upper_limit="221.5"/>
                    <measurement group_id="O2" value="32.2" lower_limit="17.5" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood - PRN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.4" lower_limit="171.8" upper_limit="350.3"/>
                    <measurement group_id="O2" value="352.1" lower_limit="230.7" upper_limit="537.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood - PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="32.4" upper_limit="65.2"/>
                    <measurement group_id="O2" value="43.4" lower_limit="29.8" upper_limit="62.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroprotection as Determined by Diphtheria Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</title>
        <description>Measurement of serum antibody levels to diphtheria toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
        <time_frame>Pre vaccination and approximately 21 days post vaccination and at Delivery</time_frame>
        <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection as Determined by Diphtheria Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</title>
          <description>Measurement of serum antibody levels to diphtheria toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
          <population>Safety Population - subjects that were randomized and received the study intervention. Participants analyzed include those that provided data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="45.8" upper_limit="77.3"/>
                    <measurement group_id="O2" value="76.3" lower_limit="59.8" upper_limit="88.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="80.1" upper_limit="98.5"/>
                    <measurement group_id="O2" value="100" lower_limit="90.5" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O2" value="100.0" lower_limit="90.5" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                    <measurement group_id="O2" value="100.0" lower_limit="89.1" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroprotection as Determined by Tetanus Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</title>
        <description>Measurement of serum antibody levels to tetanus toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
        <time_frame>21 days post vaccination</time_frame>
        <population>Safety Population - all subjects receiving the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection as Determined by Tetanus Serum Antibody Levels (Defined as ≥ 0.1 IU/mL)</title>
          <description>Measurement of serum antibody levels to tetanus toxoids, in maternal blood pre- and post-vaccination, maternal blood at delivery and infant cord blood obtained at delivery</description>
          <population>Safety Population - all subjects receiving the study intervention. Participants analyzed include those that provided data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" lower_limit="67.2" upper_limit="92.7"/>
                    <measurement group_id="O2" value="84.2" lower_limit="68.7" upper_limit="94.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="87.1" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100" lower_limit="90.5" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                    <measurement group_id="O2" value="97.3" lower_limit="85.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cord Blood</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="89.1" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroprotection as Determined by Influenza Serum Antibody Levels (≥1:40) (Pre- and Post-immunization) and Seroconversion (4-fold Rise From Baseline or a Change From &lt;1:10 to ≥1:40) )</title>
        <description>Measurement of serum antibody levels to influenza antigens in maternal blood and infant cord blood obtained at delivery</description>
        <time_frame>Pre and 21 days post vaccination and at Delivery</time_frame>
        <population>Safety Population - subjects receiving the study intervention. Participants analyzed include those that provided data.</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotection as Determined by Influenza Serum Antibody Levels (≥1:40) (Pre- and Post-immunization) and Seroconversion (4-fold Rise From Baseline or a Change From &lt;1:10 to ≥1:40) )</title>
          <description>Measurement of serum antibody levels to influenza antigens in maternal blood and infant cord blood obtained at delivery</description>
          <population>Safety Population - subjects receiving the study intervention. Participants analyzed include those that provided data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Pre-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="42.1" upper_limit="73.7"/>
                    <measurement group_id="O2" value="71.1" lower_limit="54.1" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Post-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" lower_limit="76.9" upper_limit="97.3"/>
                    <measurement group_id="O2" value="94.7" lower_limit="82.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Seroconversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="24.2" upper_limit="55.5"/>
                    <measurement group_id="O2" value="50.0" lower_limit="33.4" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Pre-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="37.4" upper_limit="69.3"/>
                    <measurement group_id="O2" value="60.5" lower_limit="43.4" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Post-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="83.5" upper_limit="99.4"/>
                    <measurement group_id="O2" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Seroconversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" lower_limit="46.9" upper_limit="77.9"/>
                    <measurement group_id="O2" value="65.8" lower_limit="48.6" upper_limit="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane: Pre-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" lower_limit="5.6" upper_limit="29.2"/>
                    <measurement group_id="O2" value="13.2" lower_limit="4.4" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane: Post-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4" lower_limit="46.9" upper_limit="77.9"/>
                    <measurement group_id="O2" value="63.2" lower_limit="46.0" upper_limit="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane: Seroconversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7" lower_limit="37.4" upper_limit="69.3"/>
                    <measurement group_id="O2" value="50.0" lower_limit="33.4" upper_limit="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket: Pre-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="16.1" upper_limit="45.5"/>
                    <measurement group_id="O2" value="47.4" lower_limit="31.0" upper_limit="64.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket: Post-Vaccination Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="62.4" upper_limit="89.4"/>
                    <measurement group_id="O2" value="81.6" lower_limit="65.7" upper_limit="92.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket: Seroconversion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="42.1" upper_limit="73.7"/>
                    <measurement group_id="O2" value="42.1" lower_limit="26.3" upper_limit="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Maternal Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.5" lower_limit="75.2" upper_limit="97.1"/>
                    <measurement group_id="O2" value="94.6" lower_limit="81.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: Cord Blood Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.4" lower_limit="86.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="93.8" lower_limit="79.2" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Maternal Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="78.6" upper_limit="98.3"/>
                    <measurement group_id="O2" value="94.6" lower_limit="81.8" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Cord Blood Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="90.7" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                    <measurement group_id="O2" value="100.0" lower_limit="89.1" upper_limit="NA">Cannot be estimated - value is already 100%</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane: Maternal Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="26.3" upper_limit="59.2"/>
                    <measurement group_id="O2" value="51.4" lower_limit="34.4" upper_limit="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane: Cord Blood Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" lower_limit="59.8" upper_limit="88.6"/>
                    <measurement group_id="O2" value="78.1" lower_limit="60.0" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket: Maternal Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="56.9" upper_limit="86.6"/>
                    <measurement group_id="O2" value="67.6" lower_limit="50.2" upper_limit="82.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Phuket: Cord Blood Seroprotection</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6" lower_limit="65.7" upper_limit="92.3"/>
                    <measurement group_id="O2" value="87.5" lower_limit="71.0" upper_limit="96.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Recruited Enrollment Period</title>
        <description>Percentage of subjects recruited during 4 month enrollment period</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>All subjects recruited and enrolled in the study</population>
        <group_list>
          <group group_id="O1">
            <title>Recruited Subjects</title>
            <description>In the study arm, this includes all subjects that were recruited and enrolled into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Recruited Enrollment Period</title>
          <description>Percentage of subjects recruited during 4 month enrollment period</description>
          <population>All subjects recruited and enrolled in the study</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility as Measured by Participant Retention (Percentage of Participants Who Complete All Visits)</title>
        <description>Percentage of participants that completed all in-person and delivery visits</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Measured by Participant Retention (Percentage of Participants Who Complete All Visits)</title>
          <description>Percentage of participants that completed all in-person and delivery visits</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Reported as Percentage of Reactogenicity Data Collected</title>
        <description>Percentage of reactogenicity data days reported (days reported / total possible days)</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Reported as Percentage of Reactogenicity Data Collected</title>
          <description>Percentage of reactogenicity data days reported (days reported / total possible days)</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6"/>
                    <measurement group_id="O2" value="93.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Reported as Percentage of Adequate Biospecimens Collected</title>
        <description>Percentage of samples collected (sample timepoints collected / total possible sample timepoints)</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Reported as Percentage of Adequate Biospecimens Collected</title>
          <description>Percentage of samples collected (sample timepoints collected / total possible sample timepoints)</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Reported as Percentage of Timely Collected Biospecimens</title>
        <description>Timeliness is defined as collected within the visit window</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Reported as Percentage of Timely Collected Biospecimens</title>
          <description>Timeliness is defined as collected within the visit window</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.0"/>
                    <measurement group_id="O2" value="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Maternal Outcomes</title>
        <description>The number of participants with adverse maternal outcomes at delivery. Missing data is data not collected or unavailable.</description>
        <time_frame>Up to the 6-week postpartum visit</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Maternal Outcomes</title>
          <description>The number of participants with adverse maternal outcomes at delivery. Missing data is data not collected or unavailable.</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-term Birth (&lt;37 weeks)</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gestational Diabetes</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gestational Hypertension</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preeclampsia</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Preeclampsia/HELLP</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Infant Outcomes Based on Medical Record Review</title>
        <description>Number of participants with adverse infant outcomes. Missing data is data not collected or unavailable.</description>
        <time_frame>approximately 2 months</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Infant Outcomes Based on Medical Record Review</title>
          <description>Number of participants with adverse infant outcomes. Missing data is data not collected or unavailable.</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Small Gestational Age (SGA): Olsen et al.</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neonatal Death</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Jaundice Requiring Phototherapy</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transient Tachypnea</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematological</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis/Rule out Infection</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Birth Weight (&lt; 2500 g)</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Chorioamnionitis</title>
        <description>Percentage of participants with clinical chorioamnionitis</description>
        <time_frame>at the time of delivery</time_frame>
        <population>Safety Population - subjects randomized and receiving study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Chorioamnionitis</title>
          <description>Percentage of participants with clinical chorioamnionitis</description>
          <population>Safety Population - subjects randomized and receiving study intervention</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Histologic Chorioamnionitis on Surgical Pathology Examination of Placental Tissue</title>
        <description>Percentage of participants with histologic chorioamnionitis on surgical pathology examination of placental tissue</description>
        <time_frame>after delivery, approximately up to 2 weeks</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Histologic Chorioamnionitis on Surgical Pathology Examination of Placental Tissue</title>
          <description>Percentage of participants with histologic chorioamnionitis on surgical pathology examination of placental tissue</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Measured by Percentage of Blood Samples in Testable Condition</title>
        <description>Percentage of blood samples received in testable condition (sufficient volume and quality)</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Measured by Percentage of Blood Samples in Testable Condition</title>
          <description>Percentage of blood samples received in testable condition (sufficient volume and quality)</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Measured by Percentage of Blood Samples in With Sufficient Volume for Testing</title>
        <description>Percentage of blood samples received with sufficient volume for testing</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Measured by Percentage of Blood Samples in With Sufficient Volume for Testing</title>
          <description>Percentage of blood samples received with sufficient volume for testing</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility as Measured by Percentage of Testable Blood Samples Completed</title>
        <description>Percentage of testable (sufficient volume and quality) blood samples completed</description>
        <time_frame>Approximately 1 year</time_frame>
        <population>Safety Population - subjects randomized and received study intervention</population>
        <group_list>
          <group group_id="O1">
            <title>Simultaneous Vaccination Arm</title>
            <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>Sequential Vaccination Arm</title>
            <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility as Measured by Percentage of Testable Blood Samples Completed</title>
          <description>Percentage of testable (sufficient volume and quality) blood samples completed</description>
          <population>Safety Population - subjects randomized and received study intervention</population>
          <units>percentage of samples</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events and SAEs are captured up to 8 days post vaccination. Subjects are followed for SAEs up to the 6-week postpartum visit. Significant infant complications or SAEs identified during the delivery visit will be followed up to the 2-month well child visit.</time_frame>
      <desc>All-cause mortality, serious adverse events, and other AEs exceeding a frequency threshold of 5% were collected and reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Simultaneous Vaccination Arm</title>
          <description>In the study arm,subjects will receive both Tdap and IIV vaccines during study visit 1.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
        <group group_id="E2">
          <title>Sequential Vaccination Arm</title>
          <description>In this study arm, subjects will receive the IIV vaccine during study visit 1. Approximately 3 weeks later, they will receive the Tdap vaccine during study visit 4.
Tetanus, Diphtheria, and Pertussis Vaccine
2016-2017 Quadrivalent Inactivated Influenza Vaccine
2017-2018 Quadrivalent Inactivated Influenza Vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Rupture</sub_title>
                <description>Uterine rupture with cesarean delivery and hysterectomy. Assessed as unrelated to vaccine.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Geeta Swamy</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-5220</phone>
      <email>geeta.swamy@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

